Abstract | BACKGROUND: METHODS AND RESULTS: From July 1999 to December 2000, Thoratec VAD was used in 11 patients. Nine (all males) were included in this study as all had laboratory profiles. Hemolysis was quantified by plasma free hemoglobin (PFHb) and hydroxybuterate dehydrogenase (HBD) levels measured daily, defined as PFHb level greater than 40 mg/L and HBD greater than 250 IU/L. Data relate to the following time intervals while the VAD was still in situ: T1 = 24 hours post-VAD insertion, T2 = 24 hours post-CVVHF start, T3 = 48 to 72 hours with the same CVVHF circuit, T4 = 24 hours post-stopping of CVVHF, and T5 = CVVHF off for over 48 hours. The mean (SD) PFHb levels were 19.6 (10.9) at T1, 31.7 (0.6) at T2, 93.7 (16.4) at T3 (p < 0.05), 32.5 (20.9) at T4, and 14.2 (3.8) at T5 (p < 0.05). These changes were paralleled by the mean (SD) HBD levels: T1 = 1,337 (616), T2 = 2,025 (509), T3 = 2,676 (1,170) (p < 0.05), T4 1,780 (618), and T5 = 1,310 (436). CONCLUSIONS: Thoratec VAD was associated with a mild degree of hemolysis. This was worsened by concomitant use of CVVHF. The effect was accentuated if the same CVVHF circuit was used for over 48 hours but was reversible within 24 hours of stopping the hemofilter.
|
Authors | Heyman Luckraz, Michael Woods, Stephen R Large, Papworth VAD Group |
Journal | The Annals of thoracic surgery
(Ann Thorac Surg)
Vol. 73
Issue 2
Pg. 546-8
(Feb 2002)
ISSN: 0003-4975 [Print] Netherlands |
PMID | 11845872
(Publication Type: Journal Article)
|
Chemical References |
- Inflammation Mediators
- Hydroxybutyrate Dehydrogenase
|
Topics |
- Adult
- Combined Modality Therapy
- Disease Progression
- Female
- Heart Failure
(surgery)
- Heart Transplantation
- Heart-Assist Devices
- Hemofiltration
- Hemoglobinometry
- Hemolysis
(physiology)
- Humans
- Hydroxybutyrate Dehydrogenase
(blood)
- Inflammation Mediators
(blood)
- Kidney Failure, Chronic
(blood)
- Male
- Middle Aged
- Risk Factors
|